MCKNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
MCKESSON CORP
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1010.43+5.59 (+0.56%)
Close on Oct 19, 2026
- Market cap
- $120.44B
- P/E (TTM)
- 27.1
- Dividend yield
- 0.31%
MCKESSON CORP revenue by segment
By business segment
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North American Pharmaceutical | $340.70B | $336.65B | $334.48B | $327.35B | $320.89B | $304.51B | – | – | – | – | – | – | 82.9% | +6.2% |
| Oncology & Multispecialty | $51.99B | $48.42B | $45.14B | $41.63B | $38.74B | $36.86B | – | – | – | – | – | – | 12.6% | +34.2% |
| Medical-Surgical Solutions | $11.63B | $11.51B | $11.49B | $11.45B | $11.45B | $11.38B | $11.36B | $11.45B | $11.33B | $11.31B | $11.17B | $11.12B | 2.8% | +1.5% |
| Prescription Technology Solutions | $5.94B | $5.81B | $5.65B | $5.52B | $5.41B | $5.22B | $5.06B | $4.89B | $4.77B | $4.77B | $4.77B | $4.69B | 1.4% | +9.8% |
| International | – | – | – | – | $14.77B | $14.72B | $14.81B | $14.59B | $14.35B | $14.13B | $13.95B | $14.76B | – | – |
| U.S. Pharmaceutical | – | – | – | – | $345.96B | $327.72B | $313.34B | $299.25B | $283.29B | $278.74B | $271.63B | $260.54B | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Mckesson's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.